SEARCH

SEARCH BY CITATION

REFERENCES

  • Andres RL, Day MC. 2000. Perinatal complications associated with maternal tobacco use. Semin Neonatol 5(3): 231241.
  • Baeten JM, Bukusi EA, Lambe M. 2001. Pregnancy complications and outcomes among overweight and obese nulliparous women. Am J Public Health 91(3): 436440.
  • Chiolero A, Bovet P, Paccaud F. 2005. Association between maternal smoking and low birth weight in Switzerland: the EDEN study. Swiss Med Wkly 135(35–36): 525530.
  • Cleary-Goldman J, Malone FD, Vidaver J, et al. FASTER Consortium. 2005. Impact of maternal age on obstetric outcome. Obstet Gynecol 105(5Pt1): 983990.
  • Cnattingius S, Bergstrom R, Lipworth L, Kramer MS. 1998. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med 338(3): 147152.
  • Cuckle H, Arbuzova S, Spencer K, et al. 2003. Frequency and clinical consequences of extremely high maternal serum PAPP-A levels. Prenat Diagn 23(5): 385388.
  • Dugoff L, Hobbins JC, Malone FD, et al. 2004. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 191(4): 14461451.
  • Goetzl L, Krantz D, Simpson JL, et al. 2004. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 104(1): 3036.
  • Krantz D, Goetzl L, Simpson JL, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. 2004. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 191(4): 14521458.
  • Koster MP, Van Leeuwen-Spruijt M, Wortelboer EJ, et al. 2008. Lack of standardization in determining gestational age for prenatal screening. Ultrasound Obstet Gynecol 32(5): 607611.
  • Krantz D, Hallahan T, Ishack S, Macri VJ, Macri JN. 2006. First-trimester maternal dried blood Down syndrome screening marker levels in early pregnancy loss. Prenat Diagn 26(12): 11371141.
  • Kristensen J, Vestergaard M, Wisborg K, Kesmodel U, Secher NJ. 2005. Pre-pregnancy weight and the risk of stillbirth and neonatal death. BJOG 112(4): 403408.
  • Liu SS, Lee FK, Lee JL, et al. 2004. Pregnancy outcomes in unselected singleton pregnant women with an increased risk of first-trimester Down syndrome. Acta Obstet Gynecol Scand 83(12): 11301134.
  • Longo DR, Kruse RL, LeFevre ML Schramm WF Stockbauer JW Howell V 1999. An investigation of social and class differences in very-low birth weight outcomes: a continuing public health concern. J Health Care Finance 25(3): 7589.
  • Morssink LP, Kornman LH, Hallahan TW, et al. 1998. Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 18(2): 147152.
  • Nese Kavak Z, Basgul A, Elter K Uygur M Gokaslan H. 2006. The efficacy of first-trimester PAPP-A and free beta hCG levels for predicting adverse pregnancy outcome. J Perinat Med 34(2): 145148.
  • Ong CY, Liao AW, Spencer K Munim S Nicolaides KH. 2000. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 107(10): 12651270.
  • Poon LC, Maiz N, Valencia C Plasencia W Nicolaides KH. 2009. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 33: 2333.
  • Romero R, Kusanovic JP, Than NG, et al. 2008. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 199(2): 122.e1122.e11.
  • Rosenberg TJ, Garbers S, Chavkin W, , et al.. 2003. Prepregnancy weight and adverse perinatal outcomes in an ethnically diverse population. Obstet Gynecol 102(5Pt1): 10221027.
  • Ross-van Dorp C. Standpoint prenatal screening (2). July 2004. URL: http://www.minvws.nl/images/IBE-2488853A_tcm19-102032.pdf. [02 July 2007].
  • Shiao SY, Andrews CM, Helmreich RJ. 2005. Maternal race/ethnicity and predictors of pregnancy and infant outcomes. Biol Res Nurs 7(1): 5566.
  • Smith GC, Crossley JA, Aitken DA, et al. 2004. First-trimester placentation and the risk of antepartum stillbirth. JAMA 292(18): 22492254.
  • Smith GC, Shah I, Crossley JA, et al. 2006. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol 107(1): 161166.
  • Smith GC, Stenhouse EJ, Crossley JA Aitken DA Cameron AD Connor JM. 2002. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, preterm birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 87(4): 17621777.
  • Spencer K, Cowans NJ. Stamatopoulou 2008. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenatal diagn 28(3): 212216.
  • Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH2005. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 25(10): 949953.
  • Tul N, Pusenjak S, Osredkar J Spencer K Novak-Antolic Z. 2003. Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenat Diagn 23(12): 990996.
  • Yaron Y, Heifetz S, Ochshorn Y Lehavi O Orr-Urtreger A. 2002. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 22(9): 778782.